Z6ÈËÉú¾ÍÊDz©

ͼƬÃû³Æ

ÐÂÎÅ×ÊѶ

ϲ±¨ | Z6ÈËÉú¾ÍÊDz©ÖÆÒ©¼¯ÍÅWP103£¨Ê¯É¼¼î¼××¢ÉäÒº£©»ñÃÀ¹úFDAÁÙ´²ÊÔÑéÐí¿É

ÈÕÆÚ£º

2025Äê01ÔÂ21ÈÕ 10:15


f8fa4a40-a28b-45e6-8c59-fabb888ee8ce 

ÃÀ¹ú¶«²¿Ê±¼ä2025Äê1ÔÂ16ÈÕ £¬ÃÀ¹úʳƷҩƷ¼à¶½¹ÜÀí¾Ö£¨FDA£©ÕýʽÐí¿ÉÁ˱¾¹«Ë¾×ÔÖ÷Ñз¢µÄʯɼ¼î¼××¢ÉäÒº£¨Ñз¢²úÆ·´úºÅWP103£©ÖÎÁÆÐÂÉú¶ùȱÑõȱѪÐÔÄÔ²¡£¨HIE£©µÄÐÂÒ©ÁÙ´²ÊÔÑ飨IND£©ÉêÇë¡£¸ÃÐí¿É±êÖ¾×ÅWP103ÐÂÒ©µÄÑз¢½øÈëÁÙ´²½×¶Î¡£

ÕâÒâζ×ÅZ6ÈËÉú¾ÍÊDz©½«ÎªÐÂÉú¶ùHIEÕâһȫÇò¼±ÐèÒ©ÎïÁÆ·¨µÄ¼²²¡ £¬µì¶¨¿ªÍØÐÔÑо¿µÄ»ù´¡£»ÔÚÈ«ÊÀ½ç·¶Î§ÄÚÊ״οª´´ÐԵؽ«Ê¯ÉÀ¼î¼×ÕâÒ»¶àÖØ»ñÒæµÄµ¨¼îõ¥Ã¸ÒÖÖÆ¼ÁÓ¦ÓÃÓÚÐÂÉú¶ùHIEÕâÒ»ÖÂËÀÖ²еÄÑÏÖØ¶ù¿Æ¼²²¡£»Ò²±êÖ¾×ÅZ6ÈËÉú¾ÍÊDz©¶ÔÖйúÔ­´´Ò©“ʯɼ¼î¼×”ÔÚÐÂÖÆ¼Á¡¢ÐÂÊÊÓ¦Ö¢´´ÐÂÑз¢¼°²¼¾ÖÈ«ÇòÊг¡µÄÓÖÒ»ÖØÒªÀï³Ì±®¡£ 

 

¹ØÓÚÐÂÉú¶ùȱÑõȱѪÐÔÄÔ²¡£¨HIE£©

HIEÊÇÓÉÐÂÉú¶ùÄÔ×é֯ȱÑõºÍÄÔѪÁ÷Á¿¼õÉÙÒýÆðµÄÒ»ÖÖÐÂÉú¶ùÄÔËðÉ˼²²¡ £¬¶Ô·¢ÓýÖеĴóÄÔÓÐÑÏÖØÓ°Ïì £¬²¢¿ÉÄܵ¼ÖÂÏÔÖøµÄËÀÍöÂʺͷ¢²¡ÂÊ¡£ÔÚÃÀ¹ú £¬HIEÿÄêÓ°Ïì´óÔ¼²»µ½10,000ÃûÓ¤¶ù£»È«Çò·¶Î§ÄÚ £¬Ã¿ÄêÔ¼75ÍòÓ¤¶ùî¾»¼ÖжȻòÖØ¶ÈHIE £¬µ¼ÖÂÔ¼400,000ÃûÓ¤¶ù»¼ÓÐÉñ¾­·¢ÓýÕϰ­¡£

Ŀǰ £¬ÃÀ¹úÉÐÎÞ»ñÅúÒ©ÎïÓÃÓÚÖÎÁÆÐÂÉú¶ùHIE¡£·¢´ï¹ú¼ÒÕë¶ÔÐÂÉú¶ùÖÐÖØ¶ÈHIEµÄ±ê×¼¸ÉÔ¤·½·¨Ö»ÄÜÊÇÖÎÁÆÐÔµÍΣ¨TH£© £¬µ«½ÓÊÜ TH ÖÎÁƵÄÖÐÖØHIEÐÂÉú¶ùÈÔÈ»»á¾­Àú»ÙÃðÐԵIJ¢·¢Ö¢£º48%µÄËÀÍö»òÖжÈ/ÖØ¶È²Ð¼²¡£Òò´Ë £¬µ±ÐÂÉú¶ù·¢ÉúHIEʱ £¬·Ç³£¼±Ð谲ȫÓÐЧµÄÖÎÁÆ £¬²¢ÇÒ¶ÔÓÚ²»ÊÊÓÃÓÚTHµÄÇáÖ¢HIE²¡ÀýÒ²ÐèÒªÓÐЧµÄÒ©ÎïÁÆ·¨¡£

 

¹ØÓÚWP103Õë¶ÔHIEµÄINDÉêÇë»ñµÃÃÀ¹úFDAÐí¿É

¹«Ë¾±¾´ÎµÄINDÅú×¼ £¬ÊÇÒÔ¹«Ë¾Ñз¢Óë¼¼ÊõÍŶӿªÕ¹µÄ¸ßÖÊÁ¿¡¢·ûºÏFDAÓëICHÒªÇóµÄÁÙ´²Ç°Ò©Ñ§£¨Ô­ÁÏÒ©¡¢ÖƼÁ£©ºÍÒ©Àí¶¾ÀíÑо¿Îª»ù´¡ £¬½áºÏÒÑÓеÄÈËÓþ­ÑéÓ밲ȫÐÔÊý¾Ý £¬FDA·¢³öStudy May Proceed£¨ÁÙ´²Ñо¿¿ÉÒÔÆô¶¯£©Í¨Öª¡£

±¾¹«Ë¾µÄʯɼ¼î¼××¢ÉäÒº £¬ÓÐÍûΪ»¼ÕßÌṩÁÆÐ§ÏÔÖø¡¢°²È«ÐԺõÄÖÎÁÆÑ¡Ôñ¡£WP103Ϊʯɼ¼î¼××¢ÉäÓÃСÈÝÁ¿Ë®Õë £¬×¨Îª·¢ÉúΧ²úÆÚȱÑõȱѪµÄ»¼¶ùÉè¼Æ¡£Ê¯É¼¼î¼××÷ΪһÖָ߻îÐÔ¡¢¸ßÑ¡ÔñÐԵĵ¨¼îõ¥Ã¸ÒÖÖÆ¼Á £¬Í¬Ê±¾ßÓÐÃâÒßµ÷½Ú¡¢¿¹Ñõ»¯Ó¦¼¤¡¢Éñ¾­Ôª±£»¤µÈ×÷Óà £¬ÇÒÄÔÄÚÉúÎïÀûÓöÈÁ¼ºÃ¡£

ÁÙ´²Ç°Ñо¿±íÃ÷ £¬ÔÚneonatal HIEÄ£ÐÍÖÐ £¬Ê¯É¼¼î¼××¢ÉäÒº²»½öÄܹ»¼ÁÁ¿ÒÀÀµÐԵĸÄÉÆÈÏÖª¡¢¼ÇÒä¡¢Ô˶¯ÄÜÁ¦ £¬¶øÇÒÏÔÖø½µµÍÁ˹£ËÀÃæ»ý¡¢ÄÔËðÉË £¬Í¬Ê± £¬Ò²ÏÔÖø½µµÍȱÑõȱѪÔì³ÉµÄÉñ¾­ÔªËÀÍö¡£

 

¹ØÓÚZ6ÈËÉú¾ÍÊDz©´´ÐÂÒ©»ñÈ«Çò·¶Î§²»¿É¶àµÃFDAË«È϶¨µÄÓÅÊÆ

¹«Ë¾ÓÚ2024Äê4Ôµ׻ñµÃFDAÊÚÓèµÄʯɼ¼î¼×ÖÎÁÆÐÂÉú¶ùȱÑõȱѪÐÔÄÔ²¡£¨HIE£©µÄº±¼û¶ù¿Æ¼²²¡ÓÃÒ©È϶¨(rare pediatric disease designation £¬RPDD) £¬ÓÖÓÚ2024Äê5Ôµ׻ñµÃFDAÊÚÓèµÄÖÎÁÆÐÂÉú¶ùHIEµÄ¹Â¶ùÒ©È϶¨(orphan drug designation, ODD)¡£×÷ΪȫÇò·¶Î§ÄÚ²»¿É¶àµÃµÄ»ñµÃFDAË«È϶¨µÄÒ©Æ· £¬RPDDºÍODDÈ·±£Á˸ßÁÙ´²¼ÛֵDZÁ¦µÄʯɼ¼î¼×µÄ¸ßÉÌÒµ¼ÛÖµ £¬°üÀ¨£º´ÓÒ©Æ·»ñÅú¿ªÊ¼µÄ7ÄêµÄÊг¡×¨ÓªÈ¨(market exclusivity)¡¢ÐÂÒ©ÉêÇë(NDA)µÄÓÅÏÈÉóÆÀÉóÅú¡¢ÐÂÒ©NDA×¢²á·ÑÓõÄÃâ³ý(Ô¼3000ÍòÈËÃñ±Ò) £¬ÒÔ¼°ÔÚÁÙ´²¿ª·¢¹ý³ÌÖиü¶àµÄFDAµÄÖ¸µ¼ÓëÖ§³Ö £¬¹²Í¬´Ù½øHIEÕâÒ»ÑÏÖØºÍΣ¼°ÉúÃüµÄ¶ù¿Æº±¼û¼²²¡Ò©ÎïµÄÑз¢¡£

±¾´ÎÉ걨µÄÐÂÉú¶ùHIEÊÊÓ¦Ö¢ £¬ÕâÒ»µ¼ÖÂÓ¤¶ùËÀÍö¡¢ÖØ´ó²Ð¼²µÄÑÏÖØ¼²²¡ £¬ÃÀ¹úÉÐÎÞ»ñÅúµÄÖÎÁÆÒ©Îï £¬´æÔÚÑÏÖØµÄδÂú×ãÁÙ´²ÐèÇó¡£¹«Ë¾ÒóÇÐÏ£Íûʯɼ¼î¼×µÄÁÆÐ§ºÍ°²È«ÐÔÄܹ»¿ìËÙÔÚÁÙ´²ÉÏ»ñµÃÑéÖ¤ £¬´Ó¶øÌî²¹ÐÂÉú¶ùHIEÖÎÁƵÄÈ«ÇòÁÙ´²ÐèÇó¡£ÆÚ´ý¾ÍÁÙ´²ÊÔÑéµÄÉêÇë»ñµÃFDAµÄ»ý¼«·´À¡ £¬ÍƽøWP103µÄ¿ìËÙ¡¢¸ßÖÊÁ¿µÄÁÙ´²¿ª·¢ £¬ÔçÈÕ½«¸üºÃµÄÁÙ´²Ñ¡Ôñ´ø¸øÈ«ÇòǧǧÍòÍòÊÜHIEÍþвµÄ»¼¶ùºÍ¼ÒÍ¥¡£

Z6ÈËÉú¾ÍÊDz©ÖÆÒ©½«³ÖÐøÍÆ½ø¸ÃÑз¢ÏîÄ¿ £¬»ý¼«×öºÃ¸ÃÏîÄ¿ÁÙ´²Ñо¿µÄ³ï±¸Ó뿪չ £¬Á¦ÇóʵÏÖWP103µÄÔçÈÕÉÏÊÐ £¬½«ÕâÒ»ÓÃÒ©¾Þ´óDZÔÚÁÙ´²ÓÅÊÆµÄÁÆ·¨´ø¸øÈ«Çò¼±Ð谲ȫÐԺá¢ÁÆÐ§Ã÷È·µÄÁÆ·¨µÄ»¼¶ùºÍËûÃǵļÒÍ¥¡£

 

¹ØÓÚZ6ÈËÉú¾ÍÊDz©Ñз¢

Z6ÈËÉú¾ÍÊDz©Ä¿Ç°½¨ÓÐÔ¼120È˵ÄÑз¢ÍŶÓ £¬Äܹ»¿ªÕ¹È«¼ÛÖµÁ´µÄÒ©Æ·Ñз¢¹¤×÷ £¬´ÓÔçÆÚ·¢ÏÖµÄÉè¼Æ¡¢»¯Ñ§¡¢ÉúÎïѧ £¬µ½ IND-enablingµÄҩѧÓëÒ©Àí¶¾ÀíÑо¿ £¬ÒÔ¼°ÁÙ´²¿ª·¢µÄ¹æ»®ÓëÔËÓª¡£Í¬Ê± £¬¹«Ë¾½¨ÓÐԺʿ¹¤×÷Õ¾¡¢²©Ê¿ºó¹¤×÷Õ¾¡¢Ê¡¼¶¼¼Êõ¡¢Ñз¢ÖÐÐĵȶà¸ö¸ß¶Ëƽ̨ £¬ÎªÒ©Æ·Ñз¢ÌṩÐÛºñµÄÈ˲ÅÓëר¼ÒÖ§³Ö¡£

¹«Ë¾Ñз¢¹ÜÏ߷ḻ £¬ÐγÉÁË´´ÐÂÒ©Ñз¢¡¢·ÂÖÆÒ©Ñз¢¡¢Ô­ÁÏÒ©Ñз¢¡¢ÖÐÒ©Ñз¢ÆëÍ·²¢½øµÄ´óÑз¢ÌåϵÓë¸ñ¾Ö¡£ÆäÖÐ £¬´´ÐÂÒ©Ñз¢¾Û½¹£¨ÖØ´ó£©Éñ¾­ÏµÍ³¼²²¡¡¢´úл¡¢×ÔÌåÃâÒß¡¢º±¼û²¡µÈËÄ´óÁìÓò £¬¼½Íû³ä·Ö·¢»Ó¹«Ë¾¶àÄêµÄÊý¾Ý»ýÀÛ £¬Îª»¼Õß´øÀ´ÁÙ´²Ø½ÐèµÄ´´ÐÂÁÆ·¨¡£

»ùÓÚ¶àÄêµÄÊý¾Ý»ýÀۺͶԴóÁ¿Êý¾ÝµÄ¶´²ì £¬Z6ÈËÉú¾ÍÊDz©´´ÐÂÒ©ÍŶÓÔÚÈ«Çò·¶Î§ÄÚÊ×´´»ñµÃʯɼ¼î¼×ÖÎÁÆÐÂÉú¶ùHIEµÄODDºÍRPDDµÄÈ϶¨ £¬²¢ÔÚ¶Ìʱ¼äÄÚÍê³É¸ßÖÊÁ¿µÄÁÙ´²Ç°¹¤×÷ £¬»ñµÃFDAµÄINDÁÙ´²Åú¼þ £¬³ä·ÖÏÔʾÁ˳¬¸ßµÄÐÂÒ©Ñз¢ÄÜÁ¦ £¬ÒÔ¼°¼ÓËÙÍÆ½ø½â¾ö»¼Õߨ½ÐèµÄרҵ¾«Éñ¡£

 

Ïà¹ØÍÆ¼ö

¡¾ÍøÕ¾µØÍ¼¡¿